Pancreatic cancer: Molecular pathogenesis and new therapeutic targets

Nature Reviews Gastroenterology and Hepatology

Volumn 6, Issue 7, 2009, Pages 412-422

  Wong, Han H ^a   Lemoine, Nicholas R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CELECOXIB; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FARNESYLTHIOSALICYLIC ACID; FOCAL ADHESION KINASE INHIBITOR; GEMCITABINE; L 778123; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; MICRORNA INHIBITOR; NOTCH3 RECEPTOR INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B INHIBITOR; PROTEIN TYROSINE KINASE INHIBITOR; RAS PROTEIN; ROMIDEPSIN; SCATTER FACTOR RECEPTOR INHIBITOR; SMAD4 PROTEIN INHIBITOR; SOMATOMEDIN C RECEPTOR INHIBITOR; SONIC HEDGEHOG PROTEIN INHIBITOR; TELOMERASE INHIBITOR; TIPIFARNIB; TRANSFORMING GROWTH FACTOR BETA INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN INHIBITOR; WNT PROTEIN INHIBITOR;

ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STEM CELL; CANCER SURVIVAL; CARCINOGENESIS; CARDIOTOXICITY; CELL THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; GENE MUTATION; HUMAN; NONHUMAN; OUTCOME ASSESSMENT; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; TARGET CELL;

ANTINEOPLASTIC AGENTS; ENZYME INHIBITORS; HUMANS; PANCREATIC NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 67650924582     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2009.89     Document Type: Review

References (124)

1. Jemal, A. et al. Cancer statistics, 2008. CA CancerJ. Clin. 58, 71-96 (2008).
2. Pancreatic section, British Society of Gastroenterology et al. Guidelines for the management of patients with pancreatic cancer periampullary and ampullary carcinomas. Gut 54 (Suppl. 5), v1-v16 (2005).
3. Burris, H. A. 3rd et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J. Clin. Oncol. 15, 2403-2413 (1997).
4. Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801-1806 (2008).
5. Almoguera, C. et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53, 549-554 (1988).
6. Toubaji, A. et al. Pilot study of mutant Ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol. Immunother. 57, 1413-1420 (2008).
7. Gjertsen, M. K. et al. Intradermal Ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma. Int. J. Cancer 92, 441-450 (2001).
8. Achtar, M. S. et al. Phase II clinical trial of mutant Ras peptide vaccine in combination with GM-CSF and IL-2 in advanced cancer patients [Abstract]. J. Clin. Oncol. 25, a3067 (2007).
9. Van Cutsem, E. et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J. Clin. Oncol. 22, 1430-1438 (2004).
10. Martin, N. E. et al. A phase I trial ofthe dual farnesyltransferase and geranylgeranyltransferase inhibitor L-778 123 and radiotherapy for locally advanced pancreatic cancer. Clin. Cancer Res. 10, 5447-5454 (2004).
11. Doss, H. H. et al. A phase I trial of romidepsin in combination with gemcitabine in patients with pancreatic and other advanced solid tumors [Abstract]. J. Clin. Oncol. 26, a2567 (2008).
12. Rudek, M. A. et al. Integrated development of S-trans. Trans-farnesylthiosalicyclic acid (FTS, salisarib) in pancreatic cancer [Abstract]. J. Clin. Oncol. 26, a4626 (2008).
13. Alberts, S. R. et al. Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma: A North Central Cancer Treatment Group phase II trial. J. Clin. Oncol. 22, 4944-4950 (2004).
14. Rejiba, S., Wack, S., Aprahamian, M. & Hajri, A. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Sci. 98, 1128-1136 (2007).
15. Brummelkamp, T. R., Bernards, R. & Agami, R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2, 243-247 (2002).
16. Rinehart, J. et al. Multicenter phase II study of the oral MEK inhibitor, C1-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J. Clin. Oncol. 22, 4456-4462 (2004).
17. Jimeno, A. et al. Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. Mol. Cancer Ther. 6, 1079-1088 (2007).
18. Takayama, Y. et al. MEK inhibitor enhances the inhibitory effect of imatinib on pancreatic cancer cell growth. Cancer Lett. 264 241-249 (2008).
19. Korc, M. et al. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J. Clin. Invest. 90, 1352-1360 (1992).
20. Bloomston, M., Bhardwaj, A., Ellison, E. C. & Frankel, W. L. Epidermal growth factor receptor expression in pancreatic carcinoma using tissue microarray technique. Dig. Surg. 23, 74-79 (2006).
21. Moore, M. J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 25, 1960-1966 (2007).
22. Grubbs, S. S., Grusenmeyer, P.A., Petrelli, N. J. & Gralla, R. J. Is it cost-effective to add erlotinib to gemcitabine in advanced pancreatic cancer? [Abstract]. J. Clin. Oncol. 24, a6048 (2006).
23. Fountzilas, G. et al. Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: A phase II study of the Hellenic Cooperative Oncology Group with biomarker evaluation. Cancer Invest. 26, 784-793 (2008).
24. Ignatiadis, M. et al. A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer. Oncology 71, 159-163 (2006).
25. Blaszkowsky, L. S. et al. A phase II study of docetaxel in combination with ZD1839 (gefitinib) in previously treated patients with metastatic pancreatic cancer [Abstract]. J. Clin. Oncol. 25, a15080 (2007).
26. Safran, H. et al. Lapatinib/gemcitabine and lapatinib/gemcitabine/ oxaliplatin: A phase I study for advanced pancreaticobiliary cancer. Am. J. Clin. Oncol. 31, 140-144 (2008).
27. Midgley, R. et al. Phase I study of GW572016 (lapatinib), a dual kinase inhibitor, in combination with irinotecan (IR), 5-fluorouracil (FU) and leucovorin (LV). J. Clin. Oncol. 23, 3086-3093 (2005).
28. Philip, P.A. et al. Phase III study ofgemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study [Abstract]. J. Clin. Oncol. 25, 4509 (2007).
29. Cascinu, S. et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: A randomised, multicentre, phase II trial. Lancet Oncol. 9, 39-44 (2008).
30. Munter, M. et al. Final results of a phase II trial [PARC-Study ISRCTN56652283] for patients with primary inoperable locally advanced pancreatic cancer combining intensity modulated radiotherapy (IMRT) with cetuximab and gemcitabine [Abstract]. J. Clin. Oncol. 26, 4613 (2008).
31. Burtness, B. A. et al. Phase II ECOG trial of irinotecan/docetaxel with or without cetuximab in metastatic pancreatic cancer: Updated survival and CA19-19 results [Abstract]. J. Clin. Oncol. 26, 4642 (2008).
32. Caplin, M. et al. Expression and processing of gastrin in pancreatic adenocarcinoma. Br. J. Surg. 87, 1035-1040 (2000).
33. Chau, I. et al. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br. J. Cancer 94 1107-1115 (2006).
34. Kawasaki, D. et al. Effect of Z-360, a novel orally active CCK-2/ gastri n receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro. Cancer Chemother. Pharmacol. 61, 883-892 (2008).
35. Meyer, T. et al. A phase IB/IIA, multicentre, randomised, double-blind placebo controlled study to evaluate the safety and pharmacokinetics of Z-360 in subjects with unresectable advanced pancreatic cancer in combination with gemcitabine [Abstract]. J. Clin. Oncol. 26, 4636 (2008).
36. Shapiro, J. et al. G17DT + gemcitabine [Gem] versus placebo + Gem in untreated subjects with locally advanced, recurrent, or metastatic adenocarcinoma of the pancreas: Results of a randomized, double-blind, multinational, multicenter study [Abstract]. J. Clin. Oncol. 23 4012 (2005).
37. Seo, Y., Baba, H., Fukuda, T., Takashima, M. & Sugimachi, K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88, 2239-2245 (2000).
38. Kindler, H. L. et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P)in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B (CALGB). J. Clin. Oncol. 25, 4508-4509 (2007).
39. Vervenne, W. et al. A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts)with metastatic pancreatic cancer. J. Clin. Oncol. 26, 4507-4509 (2008).
40. Wallace, J. A. et al. Sorafenib (S) plus gemcitabine (G) for advanced pancreatic cancer (PC): A phase II trial of the University of Chicago Phase II Consortium [Abstract]. J. Clin. Oncol. 25, 4608 (2007).
41. Spano, J. Pet al. Efficacy ofgemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: An open-label randomised phase II study. Lancet 371, 2101-2108 (2008).
42. Friess, H. et al. A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer. BMC Cancer 6, 285 (2006).
43. Evans, T. et al. Final results from cohort I of a phase II study of volociximab, an anti-α5β1 integrin antibody, in combination with gemcitabine (GEM) in patients (pts) with metastatic pancreatic cancer (MPC) [Abstract]. J. Clin. Oncol. 25, 4549 (2007).
44. Mita, M. M. et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of E7820 - an oral sulfonamide with novel, α-2 integrin mediated antiangiogenic properties: Results of a phase I study [Abstract]. J. Clin. Oncol. 23, 3082 (2005).
45. Bramhall, S. R., Rosemurgy, A., Brown, P D., Bowry, C. & Buckels, J. A. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: A randomized trial. J. Clin. Oncol. 19, 3447-3455 (2001).
46. Bramhall, S. R. et al. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer 87, 161-167 (2002).
47. Moore, M. J. et al. Comparison ofgemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: A phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. 21, 3296-3302 (2003).
48. Rugged, B. A., Huang, L., Wood, M., Cheng, J. Q. & Testa, J. R. Amplification and overexpression of the AKT2 oncogene in a subset of human pancreatic ductal adenocarcinomas. Mol. Carcinog. 21, 81-86 (1998).
49. Schlieman, M. G., Fahy, B. N., Ramsamooj, R., Beckett, L. & Bold, R. J. Incidence, mechanism and prognostic value of activated Akt in pancreas cancer. Br. J. Cancer 89, 2110-2115 (2003).
50. Asano, T. et al. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells. Oncogene 23, 8571-8580 (2004).
51. Abe, N. et al. Pancreatic duct cell carcinomas express high levels of high mobility group I(Y) proteins. Cancer Res. 60, 3117-3122 (2000).
52. Liau, S. S. & Whang, E. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma. Clin. Cancer Res. 14, 1470-1477 (2008).
53. Liau, S. S., Ashley, S. W. & Whang, E. E. Lentivirus-mediated RNA interference of HMGA1 promotes chemosensitivity to gemcitabine in pancreatic adenocarcinoma. J. Gastrointest. Surg. 10, 1254-1262 (2006).
54. Trapasso, E et al. Therapy of human pancreatic carcinoma based on suppression of HMGA1 protein synthesis in preclinical models. Cancer Gene Ther. 11, 633-641 (2004).
55. Ito, D. et al. In vivo antitumor effect of the mTOR inhibitor CCI-779 and gemcitabine in xenograft models of human pancreatic cancer. Int. J. Cancer 118, 2337-2343 (2006).
56. Wolpin, B. M. et al. Phase II study of RADO01 in previously treated patients with metastatic pancreatic cancer [Abstract]. J. Clin. Oncol. 26, 4614 (2008).
57. Azzariti, A., Porcelli, L., Gatti, G., Nicolin, A. & Paradiso, A. Synergic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors on pancreatic cancer cells. Biochem. Pharmacol. 75 1035-1044 (2008).
58. Tuncyurek, P. et al. Everolimus and mycophenolate mofetil sensitize human pancreatic cancer cells to gemcitabine in vitro: A novel adjunct to standard chemotherapy? Eur. Surg. Res. 39, 380-387 (2007).
59. Rajan, A. et al. mTOR expression in pancreatic adenocarcinoma and its correlation with survival [Abstract]. J. Clin. Oncol. 26 22169 (2008).
60. Reuter, S., Eifes, S., Dicato, M., Aggarwal, B. B. & Diederich, M. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem. Pharmacol. 76, 1340-1351 (2008).
61. Wang, Z. et al. Synergistic effects of multiple natural products in pancreatic cancer cells. Life Sci. 83, 293-300 (2008).
62. Sun, M. et al. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol. Cancer Ther. 7, 464-473 (2008).
63. Dhillon, N. et al. Phase II trial ofcurcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 14, 4491-4499 (2008).
64. Epelbaum, R., Vizel, B. & Bar-Sela, G. Phase II study of curcumin and gemcitabine in patients with advanced pancreatic cancer [Abstract]. J. Clin. Oncol. 26, 15619 (2008).
65. Alberts, S. R. et al. PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma: A North Central Cancer Treatment Group (NCCTG) randomized phase II study. Ann. Oncol. 16, 1654-1661 (2005).
66. Sloss, C. M. et al. Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells. Clin. Cancer Res. 14, 5116-5123 (2008).
67. Tucker, O. N. et al. Cyclooxygenase-2 expression is up-regulated in human pancreatic cancer. Cancer Res. 59, 987-990 (1999).
68. Ding, X. Z., Hennig, R. & Adrian, T. E. Lipoxygenase and cyclooxygenase metabolism: New insights in treatment and chemoprevention of pancreatic cancer. Mol. Cancer 2, 10 (2003).
69. Wei, D. et al. Celecoxib inhibits vascular endothelial growth factor expression in and reduces angiogenesis and metastasis of human pancreatic cancer via suppression of Spl transcription factor activity. Cancer Res. 64, 2030-2038 (2004).
70. Chuang, H. C., Kardosh, A., Gaffney, K. J., Petasis, N. A. & Schonthal, A. H. COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Mol. Cancer 7, 38 (2008).
71. Xiong, H. Q. et al. A phase II trial of gemcitabine and celecoxib for metastatic pancreatic cancer [Abstract]. J. Clin. Oncol. 23 4174 (2005).
72. Ferrari, V. et al. Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: A phase II trial. Cancer Chemother. Pharmacol. 57, 185-190 (2006).
73. Dragovich, T. et al. Gemcitabine plus celecoxib in patients with advanced or metastatic pancreatic adenocarcinoma: Results of a phase II trial. Am. J. Clin. Oncol. 31, 157-162 (2008).
74. Kerr, S. et al. Phase II trial ofgemcitabine and irinotecan plus celecoxib in advanced adenocarcinoma of the pancreas [Abstract]. J. Clin. Oncol. 23, 4155 (2005).
75. Goggins, M. et al. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res. 58, 5329-5332 (1998).
76. Levy, L. & Hill, C. S. Smad4 dependency defines two classes of transforming growth factor β (TGF-β) target genes and distinguishes TGF-β-induced epithelial-mesenchymal transition from its antiproliferative and migratory responses. Mol. Cell Biol. 25 8108-8125 (2005).
77. Melisi, D. et al. LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. Mol. Cancer Ther. 7, 829-840 (2008).
78. Medicherla, S. et al. Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment. Anticancer Res. 27, 4149-4157 (2007).
79. Hilbig, A. et al. Preliminary results of a phase I/II study in patients with pancreatic carcinoma, malignant melanoma, or colorectal carcinoma using systemic i.v. administration of AP 12009 [Abstract]. J. Clin. Oncol. 26, 4621 (2008).
80. Furukawa, T., Duguid, W. P., Kobari, M., Matsuno, S. & Tsao, M. S. Hepatocyte growth factor and Met receptor expression in human pancreatic carcinogenesis. Am. J. Pathol. 147, 889-895 (1995).
81. Tomioka, D. et al. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res. 61, 7518-7524 (2001).
82. Ogura, Y. et al. Peritumoral injection of adenovi rus vector expressing NK4 combi ned with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival. Cancer Gene Ther. 13, 520-529 (2006).
83. Jin, H. et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 68, 4360-4368 (2008).
84. Garcia, A. et al. Phase I study of ARQ 197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase 2 dose [Abstract]. J. Clin. Oncol. 25, 3525 (2007).
85. Hakam, A., Fang, Q., Karl, R. & Coppola, D. Coexpression of IGF-1R and c-Src proteins in human pancreatic ductal adenocarcinoma. Dig. Dis. Sci. 48, 1972-1978 (2003).
86. Adachi, Y. et al. Molecular targeting of IGF-I receptor for human pancreatic cancer [Abstract]. J. Clin. Oncol. 25, 14051 (2007).
87. Piao, W. et al. Insulin-like growth factor-I receptor blockade by a specific tyrosine kinase inhibitor for human gastrointestinal carcinomas. Mol. Cancer Ther. 7, 1483-1493 (2008).
88. Shen, Y. M., Yang, X. C., Yang, C. & Shen, J. K. Enhanced therapeutic effects for human pancreatic cancer by application of K-ras and I GF-I R antisense oligodeoxyn ucleotides. World J. Gastroenterol. 14 5176-5185 (2008).
89. Beltran, P. J. et al. Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models. J. Clin. Oncol. 26, 4617-4625 (2008).
90. Prewett, M. et al. IMC-A12 enhances the efficacy of cetuximab + gemcitabine therapy in human pancreatic carcinoma xenografts in AACR Meeting Abstracts 2007 652 (The American Association for Cancer Research, Philadelphia, 2007).
91. Furuyama, K. et al. Clinical significance of focal adhesion kinase in resectable pancreatic cancer. World J. Surg. 30, 219-226 (2006).
92. Liu, W. et al. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 29, 1096-1107 (2008).
93. Hatakeyama, S. et al. Anti-cancer activity of NVP-TAE226, a potent dual FAK/IGF-IR kinase inhibitor, against pancreatic carcinoma [Abstract]. J. Clin. Oncol. 24, 13162 (2006).
94. Ischenko, I. et al. Effect of Src kinase inhibition on metastasis and tumor angiogenesis in human pancreatic cancer. Angiogenesis 10, 167-182 (2007).
95. Baker, C. H. et al. Inhibition of PDGFR phosphorylation and Src and Akt activity by GN963 leads to therapy of human pancreatic cancer growing orthotopically in nude mice. Int. J. Oncol. 29, 125-138 (2006).
96. Trevino, J. G. et al. Inhibition of SRC expression and activity inhibits tumor progression and metastasis of human pancreatic adenocarcinoma cells in an orthotopic nude mouse model. Am. J. Pathol. 168, 962-972 (2006).
97. Thayer, S. P. et al. Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425, 851-856 (2003).
98. Kayed, H. et al. Indian hedgehog signaling pathway: Expression and regulation in pancreatic cancer. Int. J. Cancer 110, 668-676 (2004).
99. Berman, D. M. et al. Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract turnouts. Nature 425 846-851 (2003).
100. Shafaee, Z., Schmidt, H., Du, W., Posner, M. & Weichselbaum, R. Cyclopamine increases the cytotoxic effects of paclitaxel and radiation but not cisplatin and gemcitabine in Hedgehog expressing pancreatic cancer cells. Cancer Chemother. Pharmacol. 58, 765-770 (2006).
101. Feldmann, G. et al. Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: A new paradigm for combination therapy in solid cancers. Cancer Res. 67, 2187-2196 (2007).
102. Hu, W. G., Liu, T., Xiong, J. X. & Wang, C. Y. Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells. Acta Pharmacol. Sin. 28 1224-1230 (2007).
103. Chang, D. Z. Synthetic miRNAs targeting the GLI-1 transcription factor inhibit division and induce apoptosis in pancreatic tumor cells in AACR MeetingAbstracts 2007 639b (The American Association for Cancer Research, Philadelphia, 2006).
104. Wang, Z. et al. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol. Cancer Ther. 5, 483-493 (2006).
105. Wang, Z., Zhang, Y., Banerjee, S., Li, Y. & Sarkar, E H. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer 106, 2503-2513 (2006).
106. Dang, T., Vo, K., Washington, K. & Berlin, J. The role of Notch3 signaling pathway in pancreatic cancer [Abstract]. J. Clin. Oncol. 25, 21049 (2007).
107. Doucas, H. et al. Expression of nuclear Notch3 in pancreatic adenocarcinomas is associated with adverse clinical features, and correlates with the expression of STAT3 and phosphorylated Akt. J. Surg. Oncol. 97, 63-68 (2008).
108. Zeng, G. et al. Aberrant Wnt/beta-catenin signaling in pancreatic adenocarcinoma. Neoplasia 8, 279-289 (2006).
109. Pasca di Magliano, M. et al. Common activation of canonical Wnt signaling in pancreatic adenocarcinoma. PLoS ONE 2, e1155 (2007).
110. Nawroth, R. et al. Extracellular sulfatases, elements of the Wnt signaling pathway, positively regulate growth and tumorigenicity of human pancreatic cancer cells. PLoS ONE 2, e392 (2007).
111. Romero, D., Iglesias, M., Vary, C. P. & Quintanilla, M. Functional blockade of Smad4 leads to a decrease in beta-catenin levels and signaling activity in human pancreatic carcinoma cells. Carcinogenesis 29, 1070-1076 (2008).
112. Wang, Z. et al. Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway. Br. J. Cancer 99, 1695-1703 (2008).
113. Hermann, P. C. et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 1, 313-323 (2007).
114. Hiyama, E. et al. Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res. 57,326-331 (1997).
115. Bernhardt, S. L. et al. Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br. J. Cancer 95, 1474-1482 (2006).
116. Choudhury, A. et al. Treatment of advanced pancreatic cancer patients with a telomerase-peptide vaccine together with gemcitabine: A phase II clinical study in AACR Meeting Abstracts 2007 1863 (The American Association for Cancer Research, Philadelphia, 2007).
117. Calin, G. A. & Croce, C. M. MicroRNA signatures in human cancers. Nat. Rev. Cancer 6, 857-866 (2006).
118. Tong, A. W. & Nemunaitis, J. Modulation of miRNA activity in human cancer: A new paradigm for cancer gene therapy? Cancer Gene Ther. 15, 341-355 (2008).
119. Lee, E. J. et al. Expression profiling identifies microRNA signature in pancreatic cancer. Int. J. Cancer 120, 1046-1054 (2007).
120. Lee, C. J., Dosch, J. & Simeone, D. M. Pancreatic cancer stem cells. J. Clin. Oncol. 26, 2806-2812 (2008).
121. Olive, K. P. & Tuveson, D. A. The use of targeted mouse models for preclinical testing of novel cancer therapeutics. Clin. Cancer Res. 12, 5277-5287 (2006).
122. Lev-Ari, S. et al. Curcumin synergistically potentiates the growth inhibitory and pro-apoptotic effects of celecoxib in pancreatic adenocarci noma cells. Biomed. Pharmacother. 59 (Suppl. 2), S276-S280 (2005).
123. Kunnumakkara, A. B. et al. Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factor-κB-regulated gene products. Cancer Res. 67, 3853-3861 (2007).
124. El-Rayes, B. E, Ali, S., Sarkar, E H. & Philip, P. A. Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines. Mol. Cancer Ther. 3, 1421-1426 (2004).